Preferential pathologic complete response (pCR) by triple-negative (-) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C)

被引：9
|
作者：
Chang, H. R. [1 ]
Slamon, D. [1 ]
Gornbein, J. A. [1 ]
Chung, D. [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.604
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
604
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
    Sharma, Priyanka
    Lopez-Tarruella, Sara
    Angel Garcia-Saenz, Jose
    Khan, Qamar J.
    Gomez, Henry L.
    Prat, Aleix
    Moreno, Fernando
    Jerez-Gilarranz, Yolanda
    Barnadas, Agusti
    Picornell, Antoni C.
    del Monte-Millan, Maria
    Gonzalez-Rivera, Milagros
    Massarrah, Tatiana
    Pelaez-Lorenzo, Beatriz
    Isabel Palomero, Maria
    Gonzalez del Val, Ricardo
    Cortes, Javier
    Fuentes-Rivera, Hugo
    Bretel Morales, Denisse
    Marquez-Rodas, Ian
    Perou, Charles M.
    Lehn, Carolyn
    Wang, Yen Y.
    Klemp, Jennifer R.
    Mammen, Joshua V.
    Wagner, Jamie L.
    Amin, Amanda L.
    O'Dea, Anne P.
    Heldstab, Jaimie
    Jensen, Roy A.
    Kimler, Bruce F.
    Godwin, Andrew K.
    Martin, Miguel
    CLINICAL CANCER RESEARCH, 2018, 24 (23) : 5820 - 5829
  • [2] Differential Response of Triple-Negative Breast Cancer to a Docetaxel and Carboplatin-Based Neoadjuvant Treatment
    Chang, Helena R.
    Glaspy, John
    Allison, Mary Ann
    Kass, Frederic C.
    Elashoff, Robert
    Chung, Debra U.
    Gornbein, Jeffrey
    CANCER, 2010, 116 (18) : 4227 - 4237
  • [3] Intrinsic subtype and response to neoadjuvant chemotherapy with carboplatin and docetaxel (TCb) in triple-negative breast cancer (TNBC)
    Echavarria Diaz-Guardamino, I.
    Lopez-Tarruella, S.
    Garcia-Saenz, J. A.
    Gomez Moreno, H.
    Moreno, F.
    Jerez, Y.
    Fuentes, H.
    Marquez-Rodas, I.
    Cebollero, M.
    Del Monte-Millan, M.
    Picornell, A.
    Massarrah, T.
    Barnadas, A.
    Prat, A.
    Ballesteros Garcia, A.
    Colomer Bosch, R.
    Pelaez, B.
    Gonzalez-Rivera, M.
    Perou, C. M.
    Martin, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer
    Hatzis, Christos
    Symmans, W. Fraser
    Zhang, Ya
    Gould, Rebekah E.
    Moulder, Stacy L.
    Hunt, Kelly K.
    Abu-Khalaf, Maysa
    Hofstatter, Erin W.
    Lannin, Donald
    Chagpar, Anees B.
    Pusztai, Lajos
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 26 - 33
  • [5] Pathologic response rate (pCR) and near-pathologic response rate (near-pCR) with docetaxel-carboplatin (TCarb) in early triple-negative breast cancer.
    Kern, P.
    Kolberg, H. C.
    Kalisch, A.
    Liedtke, C.
    Otterbach, F.
    Kimmig, R.
    Kurbacher, C. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [6] Preferential pathologic complete response (pCR) in HER-2 positive and triple-negative breast cancer to sequential FEC 100-docetaxel (T) neoadjuvant chemotherapy (NCT) in stage II-III operable breast cancer
    Dubray, P.
    Durando, X.
    Abrial, C.
    Mouret-Reynier, M.
    Nayl, B.
    Thivat, E.
    Gimbergues, P.
    Achard, J.
    Chollet, P.
    Penault-Llorca, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Pathologic complete response (pCR) to neoadjuvant treatment (NAT) with carboplatin, nab-paclitaxel and anthracycline in early and locally advanced triple-negative breast cancer (TNBC).
    Miras, Isabel
    Gil, Ana
    Santos-Fernandez, Paloma
    Sanchez-Camacho, Alberto
    Falcon Gonzalez, Alejandro
    Benavent, Marta
    Cejuela Solis, Monica
    Bofill, Salvador
    Flores, Sandra
    Ruiz-Borrego, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Neoadjuvant, Anthracycline-Free Chemotherapy with Carboplatin and Docetaxel in Triple-Negative, Early-Stage Breast Cancer: A Multicentric Analysis of Feasibility and Rates of Pathologic Complete Response
    Kern, Peter
    Kalisch, Anne
    Kolberg, Hans-Christian
    Kimmig, Rainer
    Otterbach, Friederich
    von Minckwitz, Gunter
    Sikov, William M.
    Pott, Dirk
    Kurbacher, Christian
    CHEMOTHERAPY, 2013, 59 (05) : 387 - 394
  • [9] Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival
    Kern, Peter
    Kalisch, Anne
    von Minckwitz, Gunter
    Puetter, Carolin
    Kolberg, Hans-Christian
    Pott, Dirk
    Kurbacher, Christian
    Rezai, Mahdi
    Kimmig, Rainer
    JOURNAL OF CHEMOTHERAPY, 2016, 28 (03) : 210 - 217
  • [10] Pathologic response to neoadjuvant therapy with nabpaclitaxel plus carboplatin followed by anthracycline regimen in triple-negative breast cancer.
    David Cardenas, Juan
    Esteban, Carmen
    Garcia Carbonero, Iciar
    Rosero, Adriana
    Martinez Barroso, Katherin
    Borrecion Rivilla, Miguel
    Rubio Salvador, Ana Rosa
    Aguilar Anqulo, Paul Martin
    Garcia Avila, Maria
    Ignacio Chacon, Jose
    Ruiz Martin, Juan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345